Identification of SAA1 as a prognostic biomarker associated with immune infiltration in glioblastoma

References

• Ostrom QT, Cioffi G, Waite K, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–iii105.
   PubMedGoogle Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(11):1460–1469.
   PubMed Web of Science ®Google Scholar
• Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525. JAMA Oncol. 2017;3(6):784–792.
   PubMed Web of Science ®Google Scholar
• Theeler BJ, Gilbert MR. Advances in the treatment of newly diagnosed glioblastoma. BMC Med. 2015;13:293.
   PubMed Web of Science ®Google Scholar
• Siegal T. Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci. 2015;22(3):437–444.
   PubMedGoogle Scholar
• Jiang P, Liu XS. Big data mining yields novel insights on cancer. Nat Genet. 2015;47(2):103–104.
   PubMed Web of Science ®Google Scholar
• Yu C, Yin J, Wang X, et al. Association between SNAP25 and human glioblastoma multiform: a comprehensive bioinformatic analysis. Biosci Rep. 2020;40(6):BSR20200516.
   PubMedGoogle Scholar
• Xiao Y, Cui G, Ren X, et al. A novel four-gene signature associated with immune checkpoint for predicting prognosis in lower-grade glioma. Front Oncol. 2020;10:605737.
   PubMed Web of Science ®Google Scholar
• Liang Z, Li X. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer. Autoimmunity. 2021;54(2):76–87.
   PubMed Web of Science ®Google Scholar
• Lu Q, Cai P, Yu Y, et al. Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma. Autoimmunity. 2021;54(5):294–302.
   PubMedGoogle Scholar
• Unal U, Comertpay B, Demirtas TY, et al. Drug repurposing for rheumatoid arthritis: identification of new drug candidates via bioinformatics and text mining analysis. Autoimmunity. 2022;55(3):147–110.
   PubMedGoogle Scholar
• Kruthika BS, Jain R, Arivazhagan A, et al. Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma. J Neurooncol. 2019;141(2):315–325.
   PubMedGoogle Scholar
• Lambiv WL, Vassallo I, Delorenzi M, et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 2011;13(7):736–747.
   PubMedGoogle Scholar
• Zhang B, Wang Y, Li H, et al. Identification of prognostic biomarkers for multiple solid tumors using a human villi development model. Front Cell Dev Biol. 2020;8:492.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613.
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang KN, Wang Q, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genom Proteom Bioinform. 2021;19(1):1–12.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514.
   PubMed Web of Science ®Google Scholar
• Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, et al. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 2020;21(9):e419–e430.
   PubMed Web of Science ®Google Scholar
• Jensen LE, Whitehead AS. Regulation of serum amyloid a protein expression during the acute-phase response. Biochem J. 1998;334(3):489–503.
   PubMedGoogle Scholar
• Lakota K, Thallinger GG, Cucnik S, et al. Could antibodies against serum amyloid a function as physiological regulators in humans? Autoimmunity. 2011;44(2):149–158.
   PubMed Web of Science ®Google Scholar
• Takehara M, Sato Y, Kimura T, et al. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Cancer Sci. 2020;111(8):2883–2894.
   PubMed Web of Science ®Google Scholar
• Kaisman-Elbaz T, Elbaz Y, Merkin V, et al. Hemoglobin levels and red blood cells distribution width highlights glioblastoma patients subgroup with improved median overall survival. Front Oncol. 2020;10:432.
   PubMedGoogle Scholar
• Uppar AM, Sugur H, Prabhuraj AR, et al. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance. Childs Nerv Syst. 2019;35(9):1537–1545.
   PubMedGoogle Scholar
• Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402–2409.
   PubMed Web of Science ®Google Scholar
• Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–1589.
   PubMed Web of Science ®Google Scholar
• Siegmund SV, Schlosser M, Schildberg FA, et al. Serum amyloid A induces inflammation, proliferation and cell death in activated hepatic stellate cells. PLoS ONE. 2016;11(3):e0150893.
   PubMedGoogle Scholar
• Lee HY, Kim MK, Park KS, et al. Serum amyloid a stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005;330(3):989–998.
   PubMedGoogle Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525–530.
   PubMed Web of Science ®Google Scholar
• Folgueras AR, Pendás AM, Sánchez LM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48(5–6):411–424.
   PubMed Web of Science ®Google Scholar
• Park AK, Kim P, Ballester LY, et al. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro Oncol. 2019;21(1):59–70.
   PubMedGoogle Scholar
• Su R, Cao S, Ma J, et al. Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR-122. Mol Cancer. 2017;16(1):171.
   PubMedGoogle Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar
• Liang P, Chai Y, Zhao H, et al. Predictive analyses of prognostic-related immune genes and immune infiltrates for glioblastoma. Diagnostics. 2020;10(3):177.
   Web of Science ®Google Scholar
• Wei J, Marisetty A, Schrand B, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2018;129(1):137–149.
   PubMedGoogle Scholar
• Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu F, Higuchi K, et al. Serum amyloid a expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016;7(24):35843–35852.
   PubMedGoogle Scholar
• Chang SJ, Tu HP, Lai YC, et al. Increased vascular adhesion protein 1 (VAP-1) levels are associated with alternative M2 macrophage activation and poor prognosis for human gliomas. Diagnostics. 2020;10(5):256.
   Google Scholar